Drug pipeline: Q410

Antimalaria Drug Development & Pipeline

Artemisin traditionally cleave the peroxide bond by Fe(II) found in heme proteins, thus generating toxic oxygen radicals. Synthetic peroxides, thus are proving to be useful substitutes for artemisinin. The first-generation ozonide OZ277, known as arterolane [1], has been found to inhibit the growth of chloroquine-resistant (K1) and chloroquine sensitive (NF54) parasite strains. In 2012, the com...

Alzheimer's drug-development pipeline: 2016

BACKGROUND Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptom...

Alzheimer's disease drug development pipeline: 2017

INTRODUCTION There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. METHODS We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017. RESULTS There are 105 agents in the AD treatment development pipeline, of which 25 agents...

Tuberculosis drug development pipeline: progress and hope.

Improving the tuberculosis drug development pipeline.

Mycobacterium tuberculosis is considered one of the most successful pathogens and multidrug-resistant tuberculosis, a disease that urgently requires new chemical entities to be developed for treatment. There are currently several new molecules under clinical investigation in the tuberculosis (TB) drug development pipeline. However, the complex lifestyle of M. tuberculosis within the host presen...